Research output

  1. A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)

    Research output: Contribution to journal › Article › Academic › peer-review

  2. A phase ii study demonstrates no feasibility of adjuvant treatment with six cycles of s-1 and oxaliplatin in resectable esophageal adenocarcinoma, with ercc1 as biomarker for response to sox

    Research output: Contribution to journal › Article › Academic › peer-review

  3. Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study

    Research output: Contribution to journal › Article › Academic › peer-review

View all (9) »

ID: 95565